Low data variability

Our core ECG laboratory provides a centralised system for all our studies. High precision ECG acquisition in our clinic provides meaningful ECG analysis with a smaller sample size, making us the ideal choice for the integration of cardiac safety in FIH and MAD studies.

We are a leading publisher in cardiology and have publicly accessible credentials. We are proud of our integrity, our professional growth and experience in this field.

Learn more about our ECG Lab

Exceptional ECG generation

We undertake and analyse several cardiological assessments using state-of-the-art equipment to understand and explain abnormal ECG data obtained during a clinical study of a new chemical entity.

Learn more about our Cardio Analysis Services

Experts in cardiac safety

Richmond Pharmacology’s Core ECG Laboratory team are based within St George’s Hospital Medical School, London and are made up of highly experienced cardiologists headed by Professor John Camm, a key opinion leader in TQT Trials.

Learn more about our expert cardiologists

Richmond Pharmacology Appoints Dr Daniel Chapple as Commercial Director

13
July 2026

Richmond Pharmacology, the London-based contract research organisation and global leader in early phase clinical trials, announces the appointment of Dr Daniel Chapple PhD FCIM as Commercial Director.

View Article

Leadership Spotlight- Head of Pharmacy

25
June 2026

In this edition, we spotlight Konrad Wieczorek, who leads Pharmacy

View Article

Richmond Pharmacology Appoints John Hotti as Chief Technology Officer

22
April 2026

Richmond Pharmacology is pleased to announce the appointment of John Hotti as Chief Technology Officer (CTO), strengthening the company’s leadership in technology-enabled clinical research.

View Article

Latest article from our Director of Regulatory Strategy

10
April 2026

We’re pleased to share the latest article from our Director of Regulatory Strategy, Dr Lisa Campbell

View Article

Richmond supports Beam Therapeutics to make significant step forward in potential one-time gene editing treatment for Alpha-1

30
March 2026

Beam Therapeutics has announced compelling updated clinical data from its ongoing Phase 1/2 Trial of BEAM-302 as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD).

View Article

How Richmond Pharmacology Ensures End‑to‑End Data Integrity and Operational Continuity

13
March 2026

Richmond Pharmacology applies a comprehensive, four‑pillar data‑security framework designed to protect participant information...

View Article

Latest news

Leadership Spotlight - Head of Pharmacovigilance

November 16, 2026
Amina Ghareeb on Building Richmond's Pharmacovigilance Expertise
Read more

Upcoming Event

JSCPT 2026

27 - 28 November 2026
Richmond Pharmacology is excited to join the JSCPT Annual Meeting 2026 in Tokyo, Japan, on 27-28 November 2026.
View event